177Lu-PSMA-617放射性配体治疗转移性去势抵抗性前列腺癌坐骨神经转移患者一例
本文报告一例51岁转移性去势抵抗性前列腺癌患者,主诉左侧截断性坐骨神经痛和弥漫性骨痛,转诊行177Lu-PSMA筛查。治疗前68Ga-PSMA显像显示左侧坐骨神经及多发骨摄取。患者先行坐骨神经转移灶立体定向放疗(30 Gy分6次,每次5 Gy),后接受7.4 GBq 177Lu-PSMA输注。立体定向放疗后左侧截断性坐骨神经痛消失,放疗后177Lu-PSMA未对坐骨神经增加额外毒性。
要点
- 51岁转移性去势抵抗性前列腺癌患者表现为左侧截断性坐骨神经痛和弥漫性骨痛。
- 治疗前68Ga-PSMA显像显示左侧坐骨神经及多发骨摄取。
- 坐骨神经转移灶先行立体定向放疗(30 Gy分6次,每次5 Gy),后行7.4 GBq 177Lu-PSMA输注,未增加坐骨神经毒性。
核心结论
- 本病例报告一例转移性去势抵抗性前列腺癌患者存在左侧坐骨神经转移,经立体定向放疗后行177Lu-PSMA治疗,未对坐骨神经增加额外毒性。
研究设计与样本
- 病例报告,1例51岁转移性去势抵抗性前列腺癌患者。
主要发现
- 治疗前68Ga-PSMA显像显示左侧坐骨神经及多发骨摄取。
- 患者先行坐骨神经转移灶立体定向放疗(30 Gy分6次,每次5 Gy),后接受7.4 GBq 177Lu-PSMA输注。
- 立体定向放疗后左侧截断性坐骨神经痛消失。
- 立体定向放疗后177Lu-PSMA未对坐骨神经增加额外毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with metastatic castration-resistant prostate cancer usually have lymph nodes and bone metastasis. We present a rare case of a 51-year-old patient with metastatic castration-resistant prostate cancer who complained of left truncated sciatica and diffuse bone pain and who was referred for 177 Lu-prostate-specific membrane antigen (PSMA) screening. Pretreatment 68 Ga-PSMA showed left sciatic nerve and multiple bone uptake. Patient underwent stereotactic radiotherapy on the sciatic nerve metastasis (30 Gy in 6 fractions of 5 Gy) before 7.4 GBq of 177 Lu-PSMA infusions. Left truncated sciatica disappeared after stereotactic radiotherapy. No additional toxicity was added to the sciatic nerve from 177 Lu-PSMA after stereotactic radiotherapy.
引用
- Tonnelet D, Edet-Sanson A, Augusto L, et al. 177 Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis. Clin Nucl Med. 2024. PMID: 39466634. doi:10.1097/RLU.0000000000005503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。